Pfizer: Oncology Breakthroughs, GLP-1 Weight Management and Strategic M&A Insights with CFO David Denton
Description
In the latest episode of After Earnings, Pfizer CFO David Denton shares insights into the company’s achievements and future strategies with Ann Berry and Katie Perry. They discuss topics like acquiring Seagen, the use of AI in drug development, and ongoing initiatives in oncology and weight management. Denton addresses shareholder concerns about financial performance, emphasizing Pfizer’s dedication to innovation through significant investments in M&A and R&D. He also highlights the development of an oral GLP-1 receptor for obesity management and efforts to maintain robust dividends.
$PFE
00:00 START
00:55 Pfizer’s Current Position and Achievements
02:23 Strategic Acquisitions and Investments
06:04 AI and Digital Transformation in Drug Development
08:33 New Product Development: Oral Semaglutide
10:37 Challenges and Market Opportunities
15:39 Direct-to-Consumer Strategies and M&A
20:31 Investor Relations and Future Outlook
After Earnings is brought to you by Stakeholder Labs and Morning Brew.
For more go to https://www.afterearnings.com
Follow Us
X: https://twitter.com/AfterEarnings
TikTok: https://www.tiktok.com/@AfterEarnings
Instagram: https://www.instagram.com/afterearnings_ /
Reach Out
Email: afterearnings@morningbrew.com
Learn more about your ad choices. Visit megaphone.fm/adchoices
United States
